Protagenic Therapeutics, Inc.\new OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
Protagenic Therapeutics, Inc.\new (PTIX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $26.59 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2025-05-13
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2024-03-31 was $26.59K, a 44.24% decline year-over-year.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2023-09-30 was -$34.46K.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2023-06-30 was $42.29K.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2023-03-31 was $47.68K.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2024 was $26.59K, a 57.81% increase from fiscal 2023.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2023 was $16.85K.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2022 was -$421.74K.
- Protagenic Therapeutics, Inc.\new oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2021 was -$77.03K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $26.59K 10-K · filed 2025-03-31 | |||
| 2024-03-31 | $26.59K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $16.85K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$34.46K 10-Q · filed 2024-11-14 | $7.83K derived: sum of 2 quarters · filed 2024-11-14 | $55.50K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $42.29K 10-Q · filed 2024-11-14 | $89.97K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $47.68K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | -$421.74K 10-K/A · filed 2024-05-14 | |||
| 2022-09-30 | -$165.91K 10-Q · filed 2023-11-14 | -$209.33K derived: sum of 2 quarters · filed 2023-11-14 | -$360.50K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$43.42K 10-Q · filed 2023-11-14 | -$194.59K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | -$151.17K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | -$77.03K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$974.00 10-Q · filed 2022-11-14 | |||
| 2019-12-31 | $4.82K 10-K · filed 2021-03-25 | |||
| 2019-03-31 | $4.82K 10-Q · filed 2020-11-16 | |||
| 2018-12-31 | $6.25K 10-K · filed 2020-04-29 | |||
| 2018-09-30 | $1.78K 10-Q · filed 2019-11-14 | $5.32K derived: sum of 2 quarters · filed 2019-11-14 | $5.25K derived: sum of 3 quarters · filed 2019-11-14 | |
| 2018-06-30 | $3.54K 10-Q · filed 2019-11-14 | $3.47K derived: sum of 2 quarters · filed 2019-11-14 | ||
| 2018-03-31 | -$75.00 10-Q · filed 2019-11-14 | |||
| 2017-12-31 | -$1.43K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |